Fusion Antibodies (FAB) Stock Overview
A contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
FAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Fusion Antibodies plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.13 |
| 52 Week High | UK£0.21 |
| 52 Week Low | UK£0.059 |
| Beta | 1.2 |
| 1 Month Change | -8.93% |
| 3 Month Change | -7.27% |
| 1 Year Change | 109.02% |
| 3 Year Change | 104.00% |
| 5 Year Change | -90.38% |
| Change since IPO | -89.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| FAB | GB Life Sciences | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.7% | -0.3% |
| 1Y | 109.0% | 13.1% | 18.3% |
Return vs Industry: FAB exceeded the UK Life Sciences industry which returned 13.1% over the past year.
Return vs Market: FAB exceeded the UK Market which returned 18.3% over the past year.
Price Volatility
| FAB volatility | |
|---|---|
| FAB Average Weekly Movement | 9.2% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: FAB's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: FAB's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 24 | Adrian Kinkaid | www.fusionantibodies.com |
Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. It serves pharmaceutical, biotech, veterinary, diagnostic, and life science research companies.
Fusion Antibodies plc Fundamentals Summary
| FAB fundamental statistics | |
|---|---|
| Market cap | UK£15.94m |
| Earnings (TTM) | -UK£1.47m |
| Revenue (TTM) | UK£1.60m |
Is FAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAB income statement (TTM) | |
|---|---|
| Revenue | UK£1.60m |
| Cost of Revenue | UK£1.24m |
| Gross Profit | UK£352.00k |
| Other Expenses | UK£1.82m |
| Earnings | -UK£1.47m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.012 |
| Gross Margin | 22.06% |
| Net Profit Margin | -91.92% |
| Debt/Equity Ratio | 39.0% |
How did FAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/31 08:07 |
| End of Day Share Price | 2026/05/29 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fusion Antibodies plc is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robin Davison | Allenby Capital Limited |